Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company uses its peptide technology platform to discover and develop peptide-based drugs to address unmet medical needs. Its clinical programs fall under two categories of diseases, which includes hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the treatment of erythrocytosis, iron overload and other blood disorders. Its other clinical assets PTG-943 and PTG-200, are orally delivered investigational drugs in development for inflammatory bowel disease (IBD) that are designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-235 and PN-232 are in clinical development, which are IL-R antagonists. Protagonist Pty Limited is its subsidiary.

Number of employees : 79 people.
Sales per Business
20192020Delta
Peptide-based Therapeutics0.23100%28.63100% +12293.07%
USD in Million
Sales per region
20192020Delta
United States0.23100%28.63100% +12293.07%
USD in Million
Managers
Name Title Age Since
Dinesh V. Patel, Dr. President, Chief Executive Officer & Director 63 2019
Donald A. Kalkofen Chief Financial Officer 56 -
Mark L. Smythe, Dr. Vice President-Technology - 2013
David Y. Liu, Dr. Chief Scientific Officer 69 2013
Samuel R. Saks, Dr. Chief Medical Officer 65 2019
Paula O’Connor, Dr. Senior Vice President-Clinical Development - -
Harold E. Selick, Dr. Chairman 65 2014
William D. Waddill Independent Director 63 2016
Lewis T. Williams, Dr. Independent Director 70 2017
Sarah B. Noonberg, Dr. Independent Director 52 2017
Members of the board
Name Title Age Since
Harold E. Selick, Dr. Chairman 65 2014
Dinesh V. Patel, Dr. President, Chief Executive Officer & Director 63 2019
William D. Waddill Independent Director 63 2016
Lewis T. Williams, Dr. Independent Director 70 2017
Sarah B. Noonberg, Dr. Independent Director 52 2017
Bryan Giraudo Independent Director 44 2018
Sarah A. O'Dowd Independent Director 70 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,728,227 47,167,796 98.8% 0 0.0% 98.8%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 5,714,586 12.0%
Point72 Asset Management LP 4,312,300 9.07%
BVF Partners LP 3,901,759 8.21%
Consonance Capital Management LP 3,446,874 7.25%
Johnson & Johnson Innovation JJDC, Inc. 2,449,183 5.15%
Farallon Capital Management LLC 2,392,000 5.03%
The Vanguard Group, Inc. 2,233,139 4.70%
SSgA Funds Management, Inc. 2,013,979 4.24%
RTW Investments LP 1,753,695 3.69%
Lilly Ventures Management Co. LLC 1,559,060 3.28%
Company contact information
Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark, CA 94560-1160

Phone : +1.510.474.0170
Web : http://www.protagonist-inc.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Protagonist Therapeutics, Inc.
Sector Other Biotechnology & Medical Research